FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W765153079> ?p ?o ?g. }

• W765153079 endingPage "e596" @default.
• W765153079 startingPage "e589" @default.
• W765153079 abstract "We report the radiographic and clinical response rate of stereotactic body radiation therapy (SBRT) compared with conventional fractionated external beam radiation therapy (CF-EBRT) for renal cell carcinoma (RCC) bone lesions treated at our institution.Forty-six consecutive patients were included in the study, with 95 total lesions treated (50 SBRT, 45 CF-EBRT). We included patients who had histologic confirmation of primary RCC and radiographic evidence of metastatic bone lesions. The most common SBRT regimen used was 27 Gy in 3 fractions.Median follow-up was 10 months (range, 1-64 months). Median time to symptom control between SBRT and CF-EBRT were 2 (range, 0-6 weeks) and 4 weeks (range, 0-7 weeks), respectively. Symptom control rates with SBRT and CF-EBRT were significantly different (P = .020) with control rates at 10, 12, and 24 months of 74.9% versus 44.1%, 74.9% versus 39.9%, and 74.9% versus 35.7%, respectively. The median time to radiographic failure and unadjusted pain progression was 7 months in both groups. When controlling for gross tumor volume, dose per fraction, smoking, and the use of systemic therapy, biologically effective dose ≥80 Gy was significant for clinical response (hazard ratio [HR], 0.204; 95% confidence interval [CI], 0.043-0.963; P = .046) and radiographic (HR, 0.075; 95% CI, 0.013-0.430; P = .004). When controlling for gross tumor volume and total dose, biologically effective dose ≥80 Gy was again predictive of clinical local control (HR, 0.140; 95% CI, 0.025-0.787; P = .026). Toxicity rates were low and equivalent in both groups, with no grade 4 or 5 toxicity reported.SBRT is both safe and effective for treating RCC bone metastases, with rapid improvement in symptoms after treatment and more durable clinical and radiographic response rate. Future prospective trials are needed to further define efficacy and toxicity of treatment, especially in the setting of targeted agents." @default.
• W765153079 created "2016-06-24" @default.
• W765153079 creator A5003919218 @default.
• W765153079 creator A5014060810 @default.
• W765153079 creator A5016123864 @default.
• W765153079 creator A5025056006 @default.
• W765153079 creator A5028336152 @default.
• W765153079 creator A5044287083 @default.
• W765153079 creator A5052966036 @default.
• W765153079 creator A5078852725 @default.
• W765153079 creator A5079277338 @default.
• W765153079 creator A5081597269 @default.
• W765153079 creator A5088312939 @default.
• W765153079 date "2015-11-01" @default.
• W765153079 modified "2023-10-17" @default.
• W765153079 title "Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?" @default.
• W765153079 cites W1570829890 @default.
• W765153079 cites W1980275866 @default.
• W765153079 cites W1984237057 @default.
• W765153079 cites W1986920424 @default.
• W765153079 cites W1998501448 @default.
• W765153079 cites W2001438671 @default.
• W765153079 cites W2016177359 @default.
• W765153079 cites W2018876835 @default.
• W765153079 cites W2038179631 @default.
• W765153079 cites W2071248316 @default.
• W765153079 cites W2100625706 @default.
• W765153079 cites W2107814019 @default.
• W765153079 cites W2111559985 @default.
• W765153079 cites W2115646671 @default.
• W765153079 cites W2128013772 @default.
• W765153079 cites W2130693156 @default.
• W765153079 cites W2135647551 @default.
• W765153079 cites W2149669698 @default.
• W765153079 cites W2154689096 @default.
• W765153079 cites W2158738103 @default.
• W765153079 cites W2162427240 @default.
• W765153079 cites W2166459387 @default.
• W765153079 cites W2170552969 @default.
• W765153079 cites W2318044478 @default.
• W765153079 cites W4239112513 @default.
• W765153079 doi "https://doi.org/10.1016/j.prro.2015.05.004" @default.
• W765153079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4706456" @default.
• W765153079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26142027" @default.
• W765153079 hasPublicationYear "2015" @default.
• W765153079 type Work @default.
• W765153079 sameAs 765153079 @default.
• W765153079 citedByCount "54" @default.
• W765153079 countsByYear W7651530792015 @default.
• W765153079 countsByYear W7651530792016 @default.
• W765153079 countsByYear W7651530792017 @default.
• W765153079 countsByYear W7651530792018 @default.
• W765153079 countsByYear W7651530792019 @default.
• W765153079 countsByYear W7651530792020 @default.
• W765153079 countsByYear W7651530792021 @default.
• W765153079 countsByYear W7651530792022 @default.
• W765153079 countsByYear W7651530792023 @default.
• W765153079 crossrefType "journal-article" @default.
• W765153079 hasAuthorship W765153079A5003919218 @default.
• W765153079 hasAuthorship W765153079A5014060810 @default.
• W765153079 hasAuthorship W765153079A5016123864 @default.
• W765153079 hasAuthorship W765153079A5025056006 @default.
• W765153079 hasAuthorship W765153079A5028336152 @default.
• W765153079 hasAuthorship W765153079A5044287083 @default.
• W765153079 hasAuthorship W765153079A5052966036 @default.
• W765153079 hasAuthorship W765153079A5078852725 @default.
• W765153079 hasAuthorship W765153079A5079277338 @default.
• W765153079 hasAuthorship W765153079A5081597269 @default.
• W765153079 hasAuthorship W765153079A5088312939 @default.
• W765153079 hasBestOaLocation W7651530792 @default.
• W765153079 hasConcept C126322002 @default.
• W765153079 hasConcept C126838900 @default.
• W765153079 hasConcept C126894567 @default.
• W765153079 hasConcept C141071460 @default.
• W765153079 hasConcept C207103383 @default.
• W765153079 hasConcept C2777472916 @default.
• W765153079 hasConcept C2780387249 @default.
• W765153079 hasConcept C2781413609 @default.
• W765153079 hasConcept C2989005 @default.
• W765153079 hasConcept C36454342 @default.
• W765153079 hasConcept C44249647 @default.
• W765153079 hasConcept C509974204 @default.
• W765153079 hasConcept C71924100 @default.
• W765153079 hasConceptScore W765153079C126322002 @default.
• W765153079 hasConceptScore W765153079C126838900 @default.
• W765153079 hasConceptScore W765153079C126894567 @default.
• W765153079 hasConceptScore W765153079C141071460 @default.
• W765153079 hasConceptScore W765153079C207103383 @default.
• W765153079 hasConceptScore W765153079C2777472916 @default.
• W765153079 hasConceptScore W765153079C2780387249 @default.
• W765153079 hasConceptScore W765153079C2781413609 @default.
• W765153079 hasConceptScore W765153079C2989005 @default.
• W765153079 hasConceptScore W765153079C36454342 @default.
• W765153079 hasConceptScore W765153079C44249647 @default.
• W765153079 hasConceptScore W765153079C509974204 @default.
• W765153079 hasConceptScore W765153079C71924100 @default.
• W765153079 hasIssue "6" @default.
• W765153079 hasLocation W7651530791 @default.

• next